Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
The planned study is to evaluate the efficacy, safety and pharmacokinetic (PK) properties of
CPL207280 after multiple (14 days) administration in patients with type 2 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Celon Pharma SA
Collaborator:
National Center for Research and Development, Poland